eligibility_summary
Incl: ≥18, PET+ R/R B‑cell NHL, ECOG ≤2, prior anti‑CD20+anthracycline, R/R after ≥2 lines (≥1 for Burkitt/B‑LBL/MCL), relapse ≤12 mo post auto‑HSCT, or Tx‑ineligible w/ PD after ≥4 1L + SD after ≥2 2L. Excl: prior CD19 cell therapy, Richter’s, other active malignancy, CNS disease, major cardiac dz <6 mo, uncontrolled infection (treated HIV/HBV/HCV ok), autoimmune (recent systemic Tx), unmanaged VTE, auto‑HSCT <3 mo, allo‑HSCT + recent GvHD Tx, live vaccine <3 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06343311. Intervention: EB103, a biological, autologous gene‑modified T‑cell therapy. Patient T cells are collected and transduced ex vivo with a lentiviral vector encoding the EB103 transgene, then reinfused. Mechanism of action: the engineered transgene is designed to redirect and activate T cells against malignant B‑cell lymphoma cells, triggering antigen‑specific T‑cell activation, proliferation, and cytotoxic killing (CAR‑like signaling). Targets: malignant B cells in relapsed/refractory B‑cell non‑Hodgkin lymphoma, B‑cell lineage surface antigens on NHL cells, T‑cell activation/cytotoxic pathways (signal transduction and cytokine‑mediated tumor lysis). Note: prior CD19‑targeted cellular therapy is excluded.